Board of Directors

Matthew R. Stober

Mr. Stober is President and Chief Executive Officer at Istari Oncology, Inc., and a proven, experienced executive leader in the biopharmaceutical industry, having managed 10,000+ worldwide employees in various executive roles with multi-national pharmaceutical and biotechnology companies.  He has been involved in the development, approval and commercialization of dozens of pharmaceutical products, and has worked with regulators globally over the last 25 years.  Mr. Stober is an experienced team-builder, having built several green field manufacturing facilities and multi-function teams during his career. Mr. Stober managed global manufacturing and supply chain for products with worldwide sales in excess of $4 billion.  He was most recently President of Operations for Smith and Nephew, a global medical technology company.  From 2011 to 2015, Mr. Stober was in various senior leadership positions at Hospira, including Senior Vice President of Operations, and was a member of the Executive Committee. From 1999 to 2011, he held senior technical positions at several large pharmaceutical companies, including Novartis, and GlaxoSmithKline.  He is a member of the board of directors of X-Vax and is on the Catalent Biologics Technical Advisory board.  Mr. Stober has a Bachelors in Chemical Engineering from Villanova University.

Dani P. Bolognesi, PhD

Dr. Bolognesi is Chief Scientific Officer at Istari Oncology, Inc. and Professor Emeritus at Duke Medical Center, presently serving in a special capacity within Duke University Medical Center. He is chair of the Joint Steering Committee of MedBlue Incubator, Inc., an entity formed to identify and assist in the development of promising ideas, discoveries, innovations, and/or technologies from Duke faculty that have commercial potential.

His career spans all phases of drug development, and he has held a number of senior management positions. He was Founder, CEO and Chief Scientific Officer at Trimeris, Inc., a publicly traded biotechnology company that successfully obtained FDA approval for Fuzeon®, a first-in-class HIV fusion inhibitor, and he led the execution of its development and commercial collaboration with F. Hoffmann-La Roche AG. He also served as CEO and Chairman of b3Bio, Inc; CEO, Enci Therapeutics, Inc.; and CEO, C2 Regenerate, Inc.

Dr. Bolognesi’s scientific career spans three decades, during which he has held many positions at Duke University, including: James B. Duke Professor of Surgery, Professor of Microbiology/Immunology, Vice Chairman for Research and Development – Department of Surgery, Deputy Director of the Duke Comprehensive Cancer Center, and Director of the Duke University Center for AIDS Research. While at Duke, he and his research team contributed to the discovery of AZT (the first anti-HIV drug), identified the HIV protein targeted by fusion inhibitor drugs, and established a central laboratory that supported all HIV vaccine clinical trials sponsored by the National Institutes of Health. He also directed the NIH Central Laboratory for AIDS Vaccine Clinical Trials.

Robert R. Bonczek

Mr. Bonczek is Chief Administrative Officer at Istari Oncology, Inc. He is also President and Chief Financial Officer of MedBlue Incubator, Inc., and has served as President, Director, CFO and General Counsel of b3 bio, Inc.; CFO, General Counsel and Chief Administrative Officer of Trimeris, Inc.; and Chief Counsel and Global Director of Safety, Health and Environment, Dupont.

Mr. Bonczek is founding partner, Director and President of Aspen Tree Capital. He also serves on the boards of several other life science-related companies including NeurOp, Inc., Senex Biotechnology, Upstream Therapeutics, Inc., Deep Blue Medical Advances, Inc., Track X Technology, Cellective Biotherapy, Inc., and Istari Oncology, Inc.  He also serves on advisory boards for several companies, including Valence Advantage Life Sciences Fund, and Centre Partners. Mr. Bonczek received an AB in chemistry and a JD degree from the University of North Carolina. He also holds an MBA from the Wharton School at the University of Pennsylvania.

Raymond Cheong

Raymond Cheong, M.D., Ph.D. is a Principal at Baker Brothers Investments. Prior to joining Baker Brothers, Dr. Cheong completed an M.D. and a Ph.D. in Biomedical Engineering from Johns Hopkins University, where he was awarded the Michael A. Shanoff Award for best thesis research within the School of Medicine. Prior to Hopkins, he earned a B.S. in Chemical Engineering from the University of Maryland, College Park.

Sean P. Nolan

Sean P. Nolan served as President and Chief Executive officer and as a member of the Board of Directors of AveXis, Inc., from June 2015 to May 2018 when the company was acquired by Novartis. AveXis Inc. was a clinical-stage gene therapy company, dedicated to developing, manufacturing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases.

Prior to Joining AveXis, from February 2013 to April 2015, he was the chief business officer of InterMune, Inc., a biotechnology company later acquired by Roche Holding Ltd. While at InterMune, Mr. Nolan led multiple functions across the organization, including North American commercial operations, global marketing, corporate and business development and global manufacturing and supply chain. Mr. Nolan was also responsible for planning and executing the U.S. launch of InterMune’s treatment for idiopathic pulmonary fibrosis, a rare and fatal lung disease with no other approved treatments. Mr. Nolan served as chief commercial officer at Reata Pharmaceuticals, Inc. from August 2011 to December 2012, where he led the market strategy development and commercial planning for Reata Pharmaceuticals’ first in-class product pipeline. From September 2004 to November 2010, Mr. Nolan worked at Ovation Pharmaceuticals, Inc., a company focused on orphan neurology diseases. He held numerous management positions during that period including president of Lundbeck Inc., the U.S. affiliate. Ovation Pharmaceuticals was acquired by H. Lundbeck A/S in March 2009.

Mr. Nolan holds a B.A. in biology from John Carroll University. Mr. Nolan currently serves on the board of directors of Aquinox Pharmaceuticals, Inc and serves as Chairman of Encoded Therapeutics.